Qunwei Xu
Overview
Explore the profile of Qunwei Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu J, Niu Y, Li Y, Gong Y, Shi H, Huo Q, et al.
J Mater Chem B
. 2020 Apr;
5(7):1339-1352.
PMID: 32264626
In the past decade, stimuli-responsive drug delivery vehicles based on surface-functionalized mesoporous silica nanoparticles (MSNs) have attracted intense interest as a new type of drug carrier. These intelligent drug delivery...
2.
Li Y, Niu Y, Zhu J, Gao C, Xu Q, He Z, et al.
Nanoscale
. 2020 Jan;
12(4):2673-2685.
PMID: 31942900
Legumain enzyme is a well-conserved lysosomal cysteine protease and is over-expressed in many tumor cells and tumor stromal cells and exhibits higher protease activity under acidic conditions, such as in...
3.
Shi H, Xu M, Zhu J, Li Y, He Z, Zhang Y, et al.
J Mater Chem B
. 2019 Dec;
8(2):332-342.
PMID: 31825452
Recently, ultra-small platinum nanoparticles (USPtNs) have been found that can kill cancer cells by leaching Pt ions into acidic organelles, such as cell endosomes or lysosomes. Unfortunately, tumor-specific accumulation is...
4.
Xu J, Wang X, Yin H, Cao X, Hu Q, Lv W, et al.
ACS Nano
. 2019 Jul;
13(8):8577-8588.
PMID: 31339295
Ischemic stroke caused by a thrombus clog and ischemia is one of the most lethal and disabling cerebrovascular diseases. A sequentially targeted delivery system is highly desired to deliver thrombolytics...
5.
Lv W, Xu J, Wang X, Li X, Xu Q, Xin H
ACS Nano
. 2018 Jun;
12(6):5417-5426.
PMID: 29869497
Ischemic stroke is a leading cause of long-term disability and death worldwide. Current drug delivery vehicles for the treatment of ischemic stroke are less than satisfactory, in large part due...
6.
Jiang Y, Wang X, Liu X, Lv W, Zhang H, Zhang M, et al.
ACS Appl Mater Interfaces
. 2016 Dec;
9(1):211-217.
PMID: 27976583
Glioblastoma multiforme (GBM) presents one of the most lethal brain tumor with a dismal prognosis. And nanodrug delivery system (nano-DDS) have raised a lot of concern, while the conventional nanoformulations...
7.
Lv L, Jiang Y, Liu X, Wang B, Lv W, Zhao Y, et al.
Mol Pharm
. 2016 Sep;
13(10):3506-3517.
PMID: 27636161
Combining treatment of anticancer cells and antiangiogenesis is considered to be a potential targeted strategy for brain glioblastoma therapy. In this study, by utilizing the overexpression of Interleukin 13 receptor...
8.
Jiang Y, Lv L, Shi H, Hua Y, Lv W, Wang X, et al.
Colloids Surf B Biointerfaces
. 2016 Aug;
147:242-249.
PMID: 27518456
Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous system (CNS) tumor with a short survival time. The failure of chemotherapy is ascribed to the low transport...
9.
Zhao Y, Jiang Y, Lv W, Wang Z, Lv L, Wang B, et al.
J Control Release
. 2016 May;
233:64-71.
PMID: 27142584
Focal cerebral ischemia, known as stroke, causes serious long-term disabilities globally. Effective therapy for cerebral ischemia demands a carrier that can penetrate the blood-brain barrier (BBB) and subsequently target the...
10.
Wang B, Lv L, Wang Z, Jiang Y, Lv W, Liu X, et al.
Sci Rep
. 2015 Nov;
5:16589.
PMID: 26567528
Glioma presents one of the most malignant brain tumors, and the therapeutic effect is often limited due to the existence of brain tumor barrier. Based on interleukin-13 receptor α2 (IL-13Rα2)...